Discounted Cash Flow Rating

Return on Equity Rating

Debt to Equity Rating

Price to Earnings Rating

Analyst Rating

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Strong Sell

D

Virtus Stone Harbor Emerging Markets Total Income Fund (EDI)

https://www.virtus.com

Virtus Stone Harbor Emerging Markets Total Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to maximize total return, which consists of income and capital appreciation from investments in emerging markets securities.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/26/2012

Market Cap

50,296,384

Shares Outstanding

9,980,000

Weighted SO

10,019,162

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

FCO --.--%

GLO --.--%

OPP --.--%

CRF --.--%

HIE --.--%

BWG --.--%

HTY --.--%

PYN --.--%

FAX --.--%

Beta

0.0000

Last Div

0.8400

Range

4.2001-6.51

Chg

-0.0698

Avg Vol

58325

Mkt Cap

50296384

Exch

NYSE

Country

US

Phone

212-548-1200

DCF Diff

N/A

DCF

0.0000

Div Yield

0.0558

P/S

-3.2079

EV Multiple

-4.3494

P/FV

0.9331

Div Yield %

5.5777

P/E

-2.8555

PEG

0.0022

Payout

-0.5028

Current Ratio

6.2403

Quick Ratio

6.2403

Cash Ratio

1.0689

DSO

-71.6312

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

1.0000

Op Margin

0.9979

Pretax Margin

1.0290

Net Margin

1.0290

Eff Tax Rate

0.0000

ROA

-0.2023

ROE

-0.2623

ROCE

-0.1977

NI/EBT

1.0000

EBT/EBIT

1.0312

EBIT/Rev

0.9979

Debt Ratio

0.2306

D/E

0.3724

LT Debt/Cap

0.2714

Total Debt/Cap

0.2714

Int Coverage

-32.0615

CF/Debt

1.1134

Equity Multi

1.6150

Rec Turnover

-5.0955

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

-0.1966

OCF/Share

2.2311

FCF/Share

2.2311

Cash/Share

0.0693

OCF/Sales

-1.3060

FCF/OCF

1.0000

CF Coverage

1.1134

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

2.5242

P/BV

0.9331

P/B

0.9331

P/S

-3.2079

P/E

-2.8555

P/FCF

2.4564

P/OCF

2.2500

P/CF

2.2500

PEG

0.0022

P/S

-3.2079

EV Multiple

-4.3494

P/FV

0.9331

DPS

0.2800

Latest Headlines (EST)

GlobeNewswire Inc. Jun 12, 06:01 Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 15, 05:19 Down 88%, Could Editas Medicine Be a Good Investment Now? The Motley Fool Jan 08, 07:45 Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics The Motley Fool Dec 23, 08:02 Editas Just Caught a Break Thanks to Vertex Pharmaceuticals The Motley Fool Dec 23, 08:02 Editas Just Caught a Break Thanks to Vertex Pharmaceuticals MarketWatch Dec 13, 12:03 Vertex's stock heads for all-time high as non-opioid painkiller shows promise MarketWatch Dec 09, 07:47 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment MarketWatch Dec 09, 07:47 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment MarketWatch Dec 09, 07:47 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment MarketWatch Dec 08, 12:03 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment The Motley Fool Dec 04, 08:30 You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. Seeking Alpha Nov 30, 00:10 Retail And Autos In Focus: November Interim Sales Trends The Motley Fool Nov 20, 05:36 2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street GlobeNewswire Inc. Nov 03, 07:00 Editas Medicine Announces Third Quarter 2023 Results and Business Updates GlobeNewswire Inc. Nov 02, 09:12 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar The Motley Fool Oct 30, 08:30 Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient Investing.com Oct 29, 09:46 Pinterest Primed for Rich Ad Spend; Adobe a Powerhouse: Street Calls of the Week

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.07 12/07/2023 11/16/2023 12/08/2023 12/13/2023
0.07 11/09/2023 09/05/2023 11/13/2023 11/24/2023
0.07 10/11/2023 08/31/2023 10/12/2023 10/24/2023
0.07 09/08/2023 08/31/2023 09/11/2023 09/21/2023
0.07 08/10/2023 07/10/2023 08/11/2023 08/23/2023
0.07 07/19/2023 07/10/2023 07/20/2023 07/28/2023
0.05 06/09/2023 05/25/2023 06/12/2023 06/23/2023
0.07 05/10/2023 03/01/2023 05/11/2023 05/23/2023
0.07 04/12/2023 03/01/2023 04/13/2023 04/25/2023
0.07 03/10/2023 03/01/2023 03/13/2023 03/23/2023
0.07 02/10/2023 11/17/2022 02/13/2023 02/24/2023
0.07 01/06/2023 11/17/2022 01/09/2023 01/20/2023
0.07 12/12/2022 11/17/2022 12/13/2022 12/23/2022
0.07 11/07/2022 09/02/2022 11/08/2022 11/18/2022
0.07 10/07/2022 09/02/2022 10/11/2022 10/21/2022
0.07 09/12/2022 09/02/2022 09/13/2022 09/23/2022
0.07 08/08/2022 05/31/2022 08/09/2022 08/19/2022
0.07 07/11/2022 05/27/2022 07/12/2022 07/22/2022
0.07 06/06/2022 05/25/2022 06/07/2022 06/17/2022
0.07 05/09/2022 04/08/2022 05/10/2022 05/20/2022
0.07 04/08/2022 01/31/2022 04/11/2022 04/22/2022
0.07 03/07/2022 01/28/2022 03/08/2022 03/18/2022
0.07 02/07/2022 01/26/2022 02/08/2022 02/18/2022
0.07 01/07/2022 10/22/2021 01/10/2022 01/21/2022
0.07 12/10/2021 10/21/2021 12/13/2021 12/23/2021
0.07 11/08/2021 10/21/2021 11/09/2021 11/19/2021
0.07 10/08/2021 07/30/2021 10/12/2021 10/22/2021
0.07 09/13/2021 07/29/2021 09/14/2021 09/24/2021
0.07 08/09/2021 07/27/2021 08/10/2021 08/20/2021
0.07 07/16/2021 04/26/2021 07/19/2021 07/29/2021
0.07 06/11/2021 04/23/2021 06/14/2021 06/24/2021
0.07 05/14/2021 04/21/2021 05/17/2021 05/27/2021
0.08 04/16/2021 02/01/2021 04/19/2021 04/29/2021
0.08 03/12/2021 01/29/2021 03/15/2021 03/25/2021
0.08 02/11/2021 01/29/2021 02/12/2021 02/25/2021
0.08 01/14/2021 10/26/2020 01/15/2021 01/28/2021
0.08 12/17/2020 10/23/2020 12/18/2020 12/31/2020
0.08 11/05/2020 10/23/2020 11/06/2020 11/19/2020
0.08 10/16/2020 07/23/2020 10/19/2020 10/29/2020
0.08 09/11/2020 07/22/2020 09/14/2020 09/24/2020
0.08 08/14/2020 07/20/2020 08/17/2020 08/27/2020
0.08 07/17/2020 04/27/2020 07/20/2020 07/30/2020
0.08 06/12/2020 04/24/2020 06/15/2020 06/25/2020
0.08 05/14/2020 04/22/2020 05/15/2020 05/28/2020
0.15 04/17/2020 01/27/2020 04/20/2020 04/30/2020
0.15 03/13/2020 01/24/2020 03/16/2020 03/26/2020
0.15 02/13/2020 01/22/2020 02/14/2020 02/27/2020
0.15 01/16/2020 10/23/2019 01/17/2020 01/30/2020
0.15 12/12/2019 10/23/2019 12/13/2019 12/26/2019
0.15 11/07/2019 10/23/2019 11/08/2019 11/21/2019
0.15 10/18/2019 07/23/2019 10/21/2019 10/31/2019
0.15 09/13/2019 07/23/2019 09/16/2019 09/26/2019
0.15 08/16/2019 07/23/2019 08/19/2019 08/29/2019
0.15 07/12/2019 04/25/2019 07/15/2019 07/25/2019
0.15 06/14/2019 04/25/2019 06/17/2019 06/27/2019
0.15 05/16/2019 04/25/2019 05/17/2019 05/30/2019
0.15 04/11/2019 01/24/2019 04/12/2019 04/25/2019
0.15 03/15/2019 01/24/2019 03/18/2019 03/28/2019
0.15 02/14/2019 01/24/2019 02/15/2019 02/28/2019
0.15 01/17/2019 10/18/2018 01/18/2019 01/31/2019
0.15 12/13/2018 10/18/2018 12/14/2018 12/27/2018
0.15 11/15/2018 10/18/2018 11/16/2018 11/29/2018
0.15 10/12/2018 07/23/2018 10/15/2018 10/25/2018
0.15 09/14/2018 07/23/2018 09/17/2018 09/27/2018
0.15 08/17/2018 07/23/2018 08/20/2018 08/30/2018
0.15 07/13/2018 04/20/2018 07/16/2018 07/26/2018
0.15 06/15/2018 04/20/2018 06/18/2018 06/28/2018
0.15 05/17/2018 04/18/2018 05/18/2018 05/31/2018
0.15 04/13/2018 01/24/2018 04/16/2018 04/26/2018
0.15 03/16/2018 01/24/2018 03/19/2018 03/29/2018
0.15 02/08/2018 01/24/2018 02/09/2018 02/22/2018
0.15 01/11/2018 10/19/2017 01/12/2018 01/25/2018
0.15 12/14/2017 10/19/2017 12/15/2017 12/28/2017
0.15 11/16/2017 10/19/2017 11/17/2017 11/30/2017
0.15 10/13/2017 07/20/2017 10/16/2017 10/26/2017
0.15 09/15/2017 07/20/2017 09/18/2017 09/28/2017
0.15 08/17/2017 07/20/2017 08/21/2017 08/31/2017
0.15 07/13/2017 04/20/2017 07/17/2017 07/27/2017
0.15 06/15/2017 04/20/2017 06/19/2017 06/29/2017
0.15 05/11/2017 04/20/2017 05/15/2017 05/25/2017
0.15 04/12/2017 01/26/2017 04/17/2017 04/27/2017
0.15 03/16/2017 01/26/2017 03/20/2017 03/30/2017
0.15 02/08/2017 01/26/2017 02/10/2017 02/23/2017
0.04 01/11/2017 10/24/2016 01/13/2017 01/26/2017
0.04 12/14/2016 10/20/2016 12/16/2016 12/29/2016
0.05 11/03/2016 10/20/2016 11/07/2016 11/17/2016
0.02 10/13/2016 07/25/2016 10/17/2016 10/27/2016
0.02 09/15/2016 07/20/2016 09/19/2016 09/29/2016
0.01 08/11/2016 07/20/2016 08/15/2016 08/25/2016
0.04 07/14/2016 04/28/2016 07/18/2016 07/28/2016
0.02 06/16/2016 04/28/2016 06/20/2016 06/30/2016
0.15 05/12/2016 04/28/2016 05/16/2016 05/26/2016
0.15 04/14/2016 01/20/2016 04/18/2016 04/28/2016
0.15 03/16/2016 01/20/2016 03/18/2016 03/31/2016
0.15 02/10/2016 01/20/2016 02/12/2016 02/25/2016
0.15 01/13/2016 10/21/2015 01/15/2016 01/28/2016
0.15 12/16/2015 10/21/2015 12/18/2015 12/31/2015
0.15 11/05/2015 10/21/2015 11/09/2015 11/19/2015
0.15 10/15/2015 07/22/2015 10/19/2015 10/29/2015
0.15 09/10/2015 07/22/2015 09/14/2015 09/24/2015
0.15 08/13/2015 07/22/2015 08/17/2015 08/27/2015
0.15 07/16/2015 04/22/2015 07/20/2015 07/30/2015
0.15 06/11/2015 04/22/2015 06/15/2015 06/25/2015
0.15 05/13/2015 04/22/2015 05/15/2015 05/28/2015
0.15 04/16/2015 01/21/2015 04/20/2015 04/30/2015
0.15 03/12/2015 01/21/2015 03/16/2015 03/26/2015
0.15 02/11/2015 01/21/2015 02/13/2015 02/26/2015
0.15 01/14/2015 10/15/2014 01/16/2015 01/29/2015
0.15 12/04/2014 10/15/2014 12/08/2014 12/18/2014
0.15 11/06/2014 10/15/2014 11/10/2014 11/20/2014
0.15 10/16/2014 07/16/2014 10/20/2014 10/30/2014
0.15 09/11/2014 07/16/2014 09/15/2014 09/25/2014
0.15 08/14/2014 07/16/2014 08/18/2014 08/28/2014
0.15 07/17/2014 04/16/2014 07/21/2014 07/31/2014
0.15 06/12/2014 04/16/2014 06/16/2014 06/26/2014
0.15 05/14/2014 04/16/2014 05/16/2014 05/29/2014
0.15 04/10/2014 01/22/2014 04/14/2014 04/24/2014
0.15 03/13/2014 01/22/2014 03/17/2014 03/27/2014
0.15 02/12/2014 01/22/2014 02/14/2014 02/27/2014
0.15 01/15/2014 10/16/2013 01/17/2014 01/30/2014
0.15 12/11/2013 10/16/2013 12/13/2013 12/26/2013
0.15 11/06/2013 10/16/2013 11/11/2013 11/21/2013
0.15 10/17/2013 07/17/2013 10/21/2013 10/31/2013
0.15 09/12/2013 07/17/2013 09/16/2013 09/26/2013
0.15 08/15/2013 07/17/2013 08/19/2013 08/29/2013
0.15 07/11/2013 04/17/2013 07/15/2013 07/25/2013
0.15 06/13/2013 04/17/2013 06/17/2013 06/27/2013
0.15 05/15/2013 04/17/2013 05/17/2013 05/30/2013
0.15 04/11/2013 01/23/2013 04/15/2013 04/25/2013
0.15 03/14/2013 01/23/2013 03/18/2013 03/28/2013
0.15 02/13/2013 01/23/2013 02/15/2013 02/28/2013
0.15 12/19/2012 12/06/2012 12/21/2012 12/27/2012